|
Recent Developments |
|
26-JUN-13
With reference to Increase in price, Ankur Drugs and Pharma announced that no activity influencing the price movement of script is taking place in the company.
08-APR-10
Firstcall has recommended `Buy` on Ankur Drugs & Pharma with a price target of Rs 240 as against the market price (CMP) of Rs 206 in its report dated Apr. 07, 2010.
05-APR-10
The board of directors of Ankur Drugs and Pharma at its meeting held on Apr. 01, 2010, has... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Dec-2012(9) | 31-Mar-2012 (12) | 31-Mar-2011 (12) | | Net sales | 1047.00 | 1511.12 | 8239.97 | | Other Income | 0.42 | 1.86 | 8.10 | | Total Income | 1047.42 | 1512.98 | 8248.07 | | Cost of goods sold | 1101.32 | 1793.95 | 6913.08 | | OPBDIT | -53.90 | -280.97 | 1334.99 | | PAT | -1278.02 | -3074.94 | -651.30 | | Gross Block | - | - | - | | Equity capital | 193.42 | 193.42 | 193.42 | | EPS (Rs.) | - | -158.98 | -33.67 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | NA | NA | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | -5.1 | -18.6 | 16.2 | | Net margin (% of OI) | -122.0 | -203.2 | -7.9 |
|
|
Detailed Financials
|
|
|
|
|
